AMLX (Amylyx Pharmaceuticals) Float Percentage Of Total Shares Outstanding : 90.67% (As of May. 06, 2025)

View and export this data going back to 2022. Start your Free Trial

What is Amylyx Pharmaceuticals Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Amylyx Pharmaceuticals's float shares is 80.77 Mil. Amylyx Pharmaceuticals's total shares outstanding is 89.08 Mil. Amylyx Pharmaceuticals's float percentage of total shares outstanding is 90.67%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Amylyx Pharmaceuticals's Insider Ownership is 9.85%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Amylyx Pharmaceuticals's Institutional Ownership is 56.41%.

Amylyx Pharmaceuticals Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Amylyx Pharmaceuticals's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	80.77	/	89.08
	=	90.67%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amylyx Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amylyx Pharmaceuticals Inc (NAS:AMLX) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

43 Thorndike Street, Cambridge, MA, USA, 02141

Website

https://www.amylyx.com

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.

Executives

Joshua B Cohen	director, officer: Co-Chief Executive Officer	C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141
Justin B. Klee	director, officer: Co-Chief Executive Officer	C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141
Gina Mazzariello	officer: Chief Legal Officer	C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141
James M Frates	officer: Chief Financial Officer	88 SIDNEY ST, CAMBRIDGE MA 021394136
Karen Firestone	director	C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE ST., CAMBRIDGE MA 02141
Milne George M Jr	director
Daphne Quimi	director	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Patrick D Yeramian	officer: Chief Medical Officer	1815 PARKSIDE CIRCLE SOUTH, BOCA RATON FL 33486
Morningside Venture Investments Ltd	10 percent owner	MCCARTHY LEGAL SERVICES, 1188 CENTRE STREET, NEWTON CENTRE MA 02459
Margaret Olinger	officer: Chief Commercial Officer	C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Dragsa 96 Llc	10 percent owner	55 RAILROAD AVE., GREENWICH CT 06830
Als Invest 1 B.v.	10 percent owner	EERSTE WELERINGDWARSSTRAAL 54E, 1017 TP, AMSTERDAM P7 1017
Rose Sharon Shabet	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Paul R. Fonteyne	director	C/O RESTORBIO, INC., 501 BOYLSTON STREET SUITE 6102, BOSTON MA 02116